|
US4946A
(en)
|
|
1847-01-26 |
|
Improvement in carriage-wheels |
|
US778A
(en)
|
|
1838-06-12 |
|
Thomas wright |
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4740461A
(en)
|
1983-12-27 |
1988-04-26 |
Genetics Institute, Inc. |
Vectors and methods for transformation of eucaryotic cells
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
GB2183662B
(en)
|
1985-04-01 |
1989-01-25 |
Celltech Ltd |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US4959455A
(en)
|
1986-07-14 |
1990-09-25 |
Genetics Institute, Inc. |
Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
|
|
EP0281604B1
(en)
|
1986-09-02 |
1993-03-31 |
Enzon Labs Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
WO1990006952A1
(fr)
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Facteur de stimulation de colonies de granulocytes modifies chimiquement
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
FR2656800B1
(fr)
|
1990-01-08 |
1992-05-15 |
Roussy Inst Gustave |
Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
|
|
US5976877A
(en)
|
1990-01-08 |
1999-11-02 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
AU8507191A
(en)
|
1990-08-29 |
1992-03-30 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
AU3178993A
(en)
|
1991-11-25 |
1993-06-28 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
PT1589107E
(pt)
|
1992-08-21 |
2010-03-29 |
Univ Bruxelles |
Imunoglobulinas desprovidas de cadeias leves
|
|
DK0698097T3
(da)
|
1993-04-29 |
2001-10-08 |
Unilever Nv |
Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
|
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
|
ZA953629B
(en)
|
1994-05-06 |
1996-11-05 |
Roussy Inst Gustave |
Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies
|
|
US5532210A
(en)
|
1994-06-08 |
1996-07-02 |
E. I. Du Pont De Nemours And Company |
High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
JP2000508226A
(ja)
|
1995-07-21 |
2000-07-04 |
アプライド リサーチ システムズ アース ホールディング エヌ．ヴィ． |
Ｌａｇ−３タンパク質によるｔｈ１リンパ球を検出、同定、単離並びに選択的に標識およびターゲッティングする方法
|
|
AU728911B2
(en)
|
1996-11-28 |
2001-01-18 |
Institut Gustave Roussy |
Mutants of the LAG-3 proteins, products for the expression of these mutants and use
|
|
US6500422B2
(en)
|
1996-11-29 |
2002-12-31 |
Applied Research Systems Ars Holding N.V. |
Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3)
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
EP0900841A1
(en)
|
1997-06-18 |
1999-03-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
LAG-3 splice variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
KR100483494B1
(ko)
|
1998-12-01 |
2005-04-15 |
프로테인 디자인 랩스 인코포레이티드 |
감마 인터페론에 대한 인간화 항체
|
|
PL220113B1
(pl)
|
1999-01-15 |
2015-08-31 |
Genentech Inc |
Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
|
|
EP2278003B2
(en)
|
1999-04-09 |
2020-08-05 |
Kyowa Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
US7795002B2
(en)
|
2000-06-28 |
2010-09-14 |
Glycofi, Inc. |
Production of galactosylated glycoproteins in lower eukaryotes
|
|
MXPA03000105A
(es)
|
2000-06-28 |
2004-09-13 |
Glycofi Inc |
Metodo para producir glicoproteinas modificadas.
|
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
|
US7288390B2
(en)
*
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
|
EP1324779B1
(en)
|
2000-09-29 |
2011-07-20 |
Schering Corporation |
Pegylated interleukin-10
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
SE0103423D0
(sv)
|
2001-10-12 |
2001-10-12 |
Astrazeneca Ab |
Polymorphism
|
|
WO2003086310A2
(en)
|
2002-04-12 |
2003-10-23 |
Ramot At Tel Aviv University Ltd. |
Prevention of brain inflammation as a result of induced autoimmune response
|
|
EP1897548B2
(en)
|
2003-02-28 |
2024-05-22 |
The Johns Hopkins University |
T cell regulation
|
|
US7410483B2
(en)
|
2003-05-23 |
2008-08-12 |
Novare Surgical Systems, Inc. |
Hand-actuated device for remote manipulation of a grasping tool
|
|
PE20050925A1
(es)
|
2003-11-10 |
2005-11-29 |
Schering Corp |
Anticuerpo recombinante humanizado anti-interleuquina 10
|
|
ATE476993T1
(de)
|
2004-06-07 |
2010-08-15 |
Univ Ramot |
Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
|
|
TW200616662A
(en)
*
|
2004-09-10 |
2006-06-01 |
Wyeth Corp |
Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
|
|
EP1868640A1
(en)
|
2005-03-31 |
2007-12-26 |
Leiden University Medical Center |
Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
|
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
EP2240203B1
(en)
*
|
2008-02-05 |
2014-04-09 |
Bristol-Myers Squibb Company |
Alpha 5 - beta 1 antibodies and their uses
|
|
AR072999A1
(es)
*
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
ES2719496T3
(es)
*
|
2008-11-12 |
2019-07-10 |
Medimmune Llc |
Formulación de anticuerpo
|
|
US8993524B2
(en)
|
2010-03-05 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
WO2012177624A2
(en)
|
2011-06-21 |
2012-12-27 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
|
PL2726101T3
(pl)
|
2011-06-30 |
2019-01-31 |
Genzyme Corporation |
Inhibitory aktywacji komórek t
|
|
KR20140097245A
(ko)
|
2011-10-31 |
2014-08-06 |
머크 샤프 앤드 돔 코포레이션 |
개선된 특성을 갖는 항체의 제조 방법
|
|
WO2013066765A1
(en)
|
2011-11-01 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Mutation of tup1 in glycoengineered yeast
|
|
GB201120527D0
(en)
|
2011-11-29 |
2012-01-11 |
Ucl Business Plc |
Method
|
|
US9944707B2
(en)
*
|
2012-05-17 |
2018-04-17 |
Sorrento Therapeutics, Inc. |
Antibodies that bind epidermal growth factor receptor (EGFR)
|
|
CA2877286C
(en)
|
2012-06-18 |
2023-05-16 |
Yale University |
Compositions and methods for diminishing an immune response
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
WO2014028560A2
(en)
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
BR112015003851A2
(pt)
|
2012-08-21 |
2017-08-08 |
Glaxo Group Ltd |
composições compreendendo um domínio variável único e mesilato de camostato (cm)
|
|
CN104884469A
(zh)
|
2012-08-21 |
2015-09-02 |
葛兰素集团有限公司 |
包含抗体和甲磺酸卡莫司他(cm)的组合物
|
|
KR20150130462A
(ko)
|
2013-03-15 |
2015-11-23 |
다나-파버 캔서 인스티튜트 인크. |
치료 펩티드
|
|
IL240838B
(en)
|
2013-03-15 |
2022-09-01 |
Glaxosmithkline Ip Dev Ltd |
Anti-3–lag binding proteins
|
|
CN107252485A
(zh)
|
2013-04-03 |
2017-10-17 |
Ibc药品公司 |
用于诱导对疾病的免疫应答的组合疗法
|
|
KR102243062B1
(ko)
|
2013-05-02 |
2021-04-21 |
아납티스바이오, 아이엔씨. |
예정된 사멸-1에 대한 항체
|
|
US20160145355A1
(en)
|
2013-06-24 |
2016-05-26 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
JP2016531907A
(ja)
|
2013-08-02 |
2016-10-13 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． |
免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ
|
|
RS64268B1
(sr)
*
|
2013-09-20 |
2023-07-31 |
Bristol Myers Squibb Co |
Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
|
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
EP4461372A3
(en)
|
2013-11-05 |
2025-01-22 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
RU2714142C2
(ru)
|
2013-11-05 |
2020-02-12 |
Бавариан Нордик А/С |
Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки
|
|
KR20160090904A
(ko)
|
2013-12-06 |
2016-08-01 |
다나-파버 캔서 인스티튜트 인크. |
치료 펩티드
|
|
GB201322626D0
(en)
|
2013-12-19 |
2014-02-05 |
Immutep S A |
Combined preparations for the treatment of cancer
|
|
GB201322725D0
(en)
|
2013-12-20 |
2014-02-05 |
Immodulon Therapeutics Ltd |
Cancer therapy
|
|
US20170015758A1
(en)
|
2014-01-21 |
2017-01-19 |
Medimmune, Llc |
Compositions And Methods For Modulating And Redirecting Immune Responses
|
|
EP3099716A1
(en)
*
|
2014-01-28 |
2016-12-07 |
Bristol-Myers Squibb Company |
Anti-lag-3 antibodies to treat hematological malignancies
|
|
UY36032A
(es)
|
2014-03-14 |
2015-10-30 |
Novartis Ag |
Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
WO2015200828A1
(en)
|
2014-06-27 |
2015-12-30 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Conjugates for immunotherapy
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
KR20240132103A
(ko)
|
2015-01-29 |
2024-09-02 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
관문 억제제 및 백신 조합 및 면역요법을 위한 이들의 사용
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
ES2813580T3
(es)
|
2015-04-17 |
2021-03-24 |
Bristol Myers Squibb Co |
Composiciones que comprenden una combinación de ipilimumab y nivolumab
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
CN108348601B
(zh)
|
2015-07-22 |
2022-05-17 |
索伦托药业有限公司 |
与lag3结合的抗体治疗剂
|
|
HUE055469T2
(hu)
|
2015-07-29 |
2021-11-29 |
Novartis Ag |
A LAG-3 elleni antitest molekulákat tartalmazó kombinált terápiák
|